10 results
Period 1: The first objective, of period 1, is to compare the safety and efficacy of ABT-494 30 mg (QD) and 15 mg QD versus placebo on a background of csDMARD(s) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in bDMARD-…
To determine the prevalence and severity of ASA-related allergic reaction in SM patients.
Primary ObjectiveTo determine whether GWP42003-P affects the pharmacokinetic (PK) profile of stiripentol (STP) or valproate (VPA).Secondary Objective(s)To assess the safety and tolerability of GWP42003-P in the presence of STP or VPA.
Primary Objective:The primary objective of this study is to evaluate the effect of SRP-4045 and SRP-4053 (combined-active group) compared to placebo onambulation, endurance, and muscle function at Week 96, as measured by the 6-minute walk test (6MWT…
The aim of this study is to investigate the effect of the intranasal cooling (RhinoChill System) on the severity and frequency of withdrawal headache and associated symptoms in the first 7 days during standard care treatment for detoxification of…
The primary aim of this study is to examine the beneficial effects of additional dietary protein supplementation on the endurance-based exercise training-induced changes in VO2max, endurance performance, muscle strength, body composition,…
Primary objective: to establish the effectiveness of laxative therapy in children with functional abdominal pain.Secondary objective: to establish if laxative therapy is effective in all functional abdominal pain syndromes, including functional…
Objective: Identify the effect of tDCS targeting the vmPFC on empathy in persons with traits of psychopathic meanness by measuring effects on an empathy task.
Primary objectiveTo assess whether the use of alimemazine improves symptoms of allergic diseases and ADHD, as scored by the parents using standardized questionnaires (Sample Snap IV rating scales)
The primary objective of the study is to evaluate neurocognitive function with use of Praluent after 96 weeks of treatment versus placebo.